(Total Views: 594)
Posted On: 03/05/2021 8:36:22 PM
Post# of 145247
![](/m/assets/46931549/no_avatar_available_thumb.jpg)
Primary End-Point! "Survival benefit: There was a 24% reduction in all-cause mortality (primary endpoint of the study) in the leronlimab versus placebo." -CytoDyn PR 3/5/21
Boom.
https://tylerpaper.com/ap/business/cytodyn-s-...f58a8.html
Boom.
https://tylerpaper.com/ap/business/cytodyn-s-...f58a8.html
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)